Blend CJC 1295 NO DAC 5mg with GHRP-6 5mg

This blend combines CJC-1295 NO-DAC, a 29-residue analog of growth hormone-releasing hormone (GHRH), with GHRP-6, a synthetic hexapeptide that engages the growth hormone secretagogue receptor (GHS-R). The two peptides are studied together in vitro because they act on separate, complementary receptor pathways.

GHRH Receptor Engagement Research

Structural and computational research has characterized the dynamic properties of the GHRH receptor and the molecular determinants involved in GHRH binding, offering a receptor-level basis for understanding how CJC-1295 NO-DAC's retained GHRH-derived sequence is positioned to engage this receptor in laboratory studies.¹

CJC-1295 NO-DAC Stabilizing Substitutions

CJC-1295 NO-DAC carries four amino acid substitutions relative to native GRF(1-29), each addressing a distinct degradation pathway: D-alanine at position 2 blocks cleavage by dipeptidyl peptidase-IV, glutamine at position 8 prevents deamidation, and alanine at position 15 together with a leucine substitution at position 27 reduce susceptibility to oxidation.

These four changes are the structural basis researchers cite for the peptide's improved in vitro stability relative to unmodified GRF(1-29).

GHRP-6 Structural Considerations

GHRP-6's sequence includes two D-amino acid residues, D-tryptophan and D-phenylalanine, positioned at sites that would otherwise be highly susceptible to exopeptidase cleavage.

Researchers studying secretagogue peptide design have noted that this D-amino acid substitution pattern is a common strategy for conferring resistance to the L-amino-acid-specific proteolytic enzymes that would otherwise rapidly degrade an all-L-sequence peptide of comparable length.

Combined Research Applications

Because CJC-1295 NO-DAC and GHRP-6 engage separate receptors, this blend is studied for research examining potential convergence of GHRH-receptor and GHS-R signaling pathways within a single controlled experimental platform.

Combined use of these peptides remains an area of exploratory laboratory research, and available data on interaction effects between the two components is preliminary and not considered conclusive.

Analytical Verification for Blended Products

For a two-component blend combining a 29-residue peptide with a considerably shorter hexapeptide, analytical verification is understood to require confirmation of both components' individual identity and purity, along with the ratio between them.

Researchers reviewing documentation for this blend are encouraged to look for individual HPLC or mass spectrometry data for CJC-1295 NO-DAC and GHRP-6 separately.

Storage and Handling in the Laboratory Setting

CJC-1295 NO-DAC's longer chain length and GHRP-6's dual tryptophan-derived residues each introduce their own routes of degradation, making the blend's more conservative handling requirement the relevant standard for the combined vial.

The lyophilized blend is stored under sub-zero freezer conditions, with the powder kept away from prolonged light exposure given GHRP-6's photosensitive tryptophan content.

Important Notice

This product is strictly intended for in vitro laboratory research and is not for human consumption, diagnostic use, or therapeutic purposes. This product has not been evaluated for safety or efficacy in humans. Researchers utilize this product to investigate growth hormone-related receptor signaling mechanisms in experimental settings.

Product Information

This peptide combination is supplied as a lyophilized powder at a concentration of 10 mg per vial (5 mg of each peptide).

References

1. Matsoukas MT, Spyroulias GA. Dynamic properties of the growth hormone-releasing hormone receptor (GHRHR) and molecular determinants of GHRH binding. Mol Biosyst. 2017;13(7):1313-1322.